COVID-19 WEEKLY REPORT 3/18/21

Total Cases

Total Tests



Projection Models from The Institute for Health Metrics and Evaluation (IHME)

https://covid19.healthdata.org/united-states-of-america?view=total-deaths&tab=trend

US COVID-19 Cases Caused by Variants

Variant	Reported Cases in US	Number of Jurisdictions Reporting
B.1.1.7	4686	50
B.1.351	142	25
P.1	27	12

Cases of Variants of Concern in the United States*†

Cases of Variants of Concern in the United States*†



DAILY TRENDS IN NUMBER OF CASES:

Current Average: 51,954; 7-day moving avg: 54,421

(54,276/63,938 two weeks ago)



DISTRIBUTION PER CASE RATE REPORTED LAST 7 DAYS



State/Territory	7-Day Case Rate per 100,000
New York City*	296.4
New Jersey	287.3
Rhode Island	233.4
Delaware	212.8
New York*	202.5
Michigan	166.3
Alabama	165.2
Connecticut	163
Florida	144.6
Alaska	142.4
Massachusetts	140.1
Pennsylvania	137.3
New Hampshire	133.7
Tennessee	130.3
South Carolina	124.7
Idaho	124.1
Kentucky	123
Vermont	122
Minnesota	120.9
West Virginia	120.7
South Dakota	117.3
Montana	117.1
District of Columbia	116.2
Colorado	116.1
North Carolina	108.8
Texas	108.5
Virginia	106.5
Utah	106.4
Mississippi	106.1
Iowa	100.8
Maryland	100.4
Nevada	97.2
Georgia	92.4
Ohio	90.7

North Dakota	87.8
Illinois	87.5
Maine	84.4
Nebraska	84.1
Arizona	83.5
Oklahoma	82.5
Louisiana	78.1
Indiana	77.5
Missouri	76.4
Arkansas	68.7
New Mexico	68
Wisconsin	67.3
Wyoming	65.7
Washington	61.8
Kansas	60.7
California	57.7
Oregon	48.4
Puerto Rico	39.9
Hawaii	25.4
Guam	12.1
Virgin Islands	11.5

PERCENT CHANGE IN CASES FROM PREVIOUS 7 DAYS



-25.01% or less | -25% - -10.01% | -10% - 0.01% | 0% - 10% | 10.01% - 25% | 25.01% or more | No Data

DAILY TRENDS IN NUMBER OF DEATHS

Current Average: 995; 7-day Moving Average: 1,111

(1,959/1,933 two weeks ago)



Death Rate Reported to the CDC Last 7 Days



Global Cases Per Johns Hopkins University



Cases by Age Group:

Download

Data from 22,473,415 cases. Age group was available for 22,301,816 (99%) cases.



Deaths by Age Group:

Download

Data from 394,004 deaths. Age group was available for 393,969 (99%) deaths.



Cases by Sex:

Download

Data from 22,473,415 cases. Sex was available for 22,205,619 (98%) cases.

All Age Groups



Deaths by Sex:

Download

Data from 394,004 deaths. Sex was available for 392,886 (99%) deaths.

All Age Groups



Confirmed COVID-19 Cases and Deaths in US Correctional and Detention Facilities By State



Jurisdiction	Cases	Deaths	Facilities
California*	83,497	254	98
Texas	47,852	302	153
Michigan	29,761	148	47
Florida*	26,348	220	24
Arizona*	20,953	63	29
Illinois	20,641	18	49
Pennsylvania*	19,344	120	46
New York*	16,672	85	63
Wisconsin*	14,316	25	45
Ohio	12,829	153	37
Colorado*	12,344	33	27
Arkansas*	12,215	2	3
North Carolina	11,074	84	59
Kentucky	10,895	67	22
Virginia	10,568	63	46
New Jersey	9,385	56	36
Oklahoma*	9,282	56	4

Pregnant women

Pregnant women[1] with COVID-19, United States, January 22, 2020 - March 15, 2021

TOTAL CASES[1]	TOTAL DEATHS
78,129	85

Healthcare Personnel

HEALTHCARE PERSONNEL CASES	HEALTHCARE PERSONNEL DEATHS
446,679	1,454

Percentage of ED visits by syndrome in United States: COVID-19-Like Illness, Shortness of Breath, Pneumonia, and Influenza-Like Illness



COVID-19 Vaccinations in the United States

Total Vaccine Doses

Delivered	147,590,615
Administered	113,037,627

Learn more about the distribution of vaccines.

People Vaccinated	At Least One Dose	Fully Vaccinated
Total	73,669,956	39,989,196
% of Total Population	22.2%	12%
Population ≥ 18 Years of Age	73,510,051	39,937,436
% of Population ≥ 18 Years of Age	28.5%	15.5%
Population ≥ 65 Years of Age	35,784,219	20,549,637
% of Population ≥ 65 Years of Age	65.4%	37.6%

Read more about how these data are reported.

CDC | Data as of: Mar 17 2021 6:00am ET | Posted: Mar 17 2021 1:37PM ET

Total Doses Administered Reported to the CDC by State/Territory and for Select Federal Entities per 100,000 of the Total Population



Daily Count of Total Doses Administered and Reported to the CDC by Date Administered, United States



Federal Pharmacy Partnership for Long-Term Care (LTC) Program

Overall US COVID-19 Vaccine Distribution and Administration; Maps, charts, and data provided by CDC, updated daily by 8 pm ET†

Total Number of Doses Administered in Long-Term Care Facilities	Number of People with at least One Dose in Long-Term Care Facilities	Number of People Fully Vaccinated in Long-Term Care Facilities
7,585,936	4,787,327	2,754,743

CDC | Data as of: Mar 17 2021 6:00am ET | Posted: Mar 17 2021 1:37PM ET

Total Doses Administered Reported to CDC by State/Territory, Federal Pharmacy Partnership for LTC Program




Number of People with at least One Dose in Long-Term Care Facilities
Person Type
Residents
2,097,298
Staff
1,563,309
Not Reported
1,126,720
0.0
200k
400k
600k
800k
1.0M
1.2M
1.4M
1.6M
1.8M
2.0M
Number of People


Number of Fully Vaccinated People in Long-Term Care Facilities
Person Type
Residents
1,417,366
Staff
979,232
Not Reported
358,145
0.0
200k
400k
600k
800k
1.0M
1.2M
1.4M
1.6M
1.8M
2.0M
Number of People

Age Groups of People with at least One Dose Administered:

Download

Data from 73,669,956 people with at least one dose administered. Age was available for 67,919,367 (92%) people with at least one dose administered.



Age Groups of People Fully Vaccinated:

Download

Data from 39,989,196 people with 2 doses administered. Age was available for 37,047,759 (92%) people fully vaccinated.



Sex of People with at least One Dose Administered:

Download

Data from 73,669,956 people with at least one dose administered. Sex was available for 67,000,229 (90.9%) people with at least one dose administered.



Sex of People Fully Vaccinated:

Download

Data from 39,989,196 people fully vaccinated. Sex was available for 36,562,799 (91.4%) people fully vaccinated.





CT DPH

COVID-19 Epidemiology: Risk of community spread of COVID-19 remains moderate-to-high throughout Connecticut.

- CT DPH continues to work with laboratories across the state to genetically sequence SARS-CoV-2 viruses. Among those genetically sequenced, the proportion of B.1.1.7 ("UK") variant is increasing.
- As predicted in MMWR: Emergence of SARS-CoV-2 B.1.1.7 Lineage, B.1.1.7 will likely become the predominant strain in Connecticut this month. This strain spreads more easily than the "wild-type" SARS-CoV-2 virus. All currently authorized vaccines in the U.S. have efficacy against B.1.1.7, however no vaccine is 100% effective. Masks and physical distancing are still recommended in public places, regardless of vaccination status.
- Updates on SARS-CoV-2 variants in Connecticut will be included in the CT COVID-19 weekly reports each Thursday.
- The majority of the of variant cases in Connecticut are identified at a laboratory at the Yale School of Public Health and are summarized here.
- While the number of variants continues to increase in CT, it is important to note that guidance and recommendations for infection control and prevention are no different for these variants than the original strain.

COVID-19 Vaccines: Due to an anticipated increase in vaccine supply, as well as progress in the vaccine rollout thus far, Governor Lamont announced an accelerated schedule for COVID-19 vaccines.

- On Friday, March 19, vaccine eligibility will expand to ages 45 years and older. Scheduling of individuals under 55 should not begin until Friday morning.

- This will be the last age-based rollout. *Tentatively*, all individuals over the age of 16 will be eligible for vaccination on April 5
- During the month of April, the state will work with providers and the Department of Developmental Services to accelerate access for the most medically high-risk individuals under 45.
- To reach CT residents who may be homebound, CT DPH has created a Homebound Individual Intake Form. Submissions will be used to connect homebound COVID-19 vaccination needs with those offering homebound COVID-19 vaccination services.
    - Individuals who meet "homebound resident" criteria include those who are physically unable to go to a vaccination clinic or mass vaccination site with or without assistance.
    - Homebound individuals must also have no prior history of anaphylaxis or severe allergic reaction requiring the use of an epinephrine auto-injector (e.g., EpiPen).

There are ongoing clinical trials evaluating **safety and efficacy of vaccines in pregnant people**. CDC and the FDA have safety monitoring systems in place to gather information about vaccination during pregnancy.

- CDC is inviting people who received a COVID-19 vaccine within 30 days prior to their last menstrual period **OR** during pregnancy to participate in the v-safe COVID-19 Vaccine Pregnancy Registry.
- Anyone previously enrolled in v-safe reporting that they were pregnant at the time of vaccination or after vaccination may be contacted by CDC for more information.

COVID-19 Control Measures: Last week CDC updated the Infection Prevention and Control Recommendations pertaining to fully vaccinated health care personnel (HCP) and fully vaccinated patients/residents within healthcare settings.

- Fully vaccinated HCP (≥14 days post second dose of a two-dose series or ≥14 days post single dose vaccine) who are asymptomatic after a higher-risk exposure **do not** need to be restricted from work for 14 days following their exposure. However, work restriction should be considered after a higher-risk exposure for fully vaccinated HCP who have an underlying immunocompromising condition (e.g., organ transplantation, cancer treatment).
- Due to the limited information about vaccine effectiveness in the high-risk population, fully vaccinated inpatients and residents in healthcare settings should continue to quarantine for 14 days following prolonged close contact with someone with SARS-CoV-2 infection.
- Fully vaccinated individuals admitted to a post-acute care facility who have **not** had prolonged close contact with someone with SARS-CoV-2 infection in the prior 14 days **no longer** need to quarantine on admission.

COVID-19 Testing:

- CDC has updated recommendations for testing **fully vaccinated people who remain asymptomatic after exposure** to someone with suspected or confirmed COVID-19 in non-healthcare settings:
    - COVID-19 testing is generally not needed in this situation.
    - Fully vaccinated **residents of non-healthcare congregate settings** (e.g., correctional and detention facilities, group homes) **should continue test for SARS-CoV-2 following exposure**. This is because residential congregate settings may face high turnover of residents, a higher risk of transmission, and challenges in maintaining recommended physical distancing.

    - Fully vaccinated **employees of non-healthcare congregate settings and other high-density workplaces with serial screening test programs** should continue **testing following exposure.**
    - Fully vaccinated people should still monitor for symptoms of COVID-19 for 14 days following an exposure. If symptoms develop, they should isolate themselves from others and be clinically evaluated for COVID-19.
- Recommendations for SARS-CoV-2 testing for HCP, residents and patients remain unchanged. Post-exposure testing is still recommended *in healthcare settings* for fully-vaccinated people.
- There are no current recommendations for serology testing after vaccination.

CT DPH Provider Call-In: Please join us on **Friday, March 19 at noon** for our first "Call-In" with the CT DPH Infectious Diseases Section. We will recap recent CDC and CT DPH updates and provide an opportunity for Q&A. Register at: https://us02web.zoom.us/meeting/register/tZApcOCgqDsqHNYNmNe81S4x2hfGpVMGgWYF

Vivian Leung, MD
Infectious Diseases Section
Connecticut Department of Public Health

Connecticut COVID-19 Summary

Summary for the most recent day of reporting. Includes confirmed plus probable cases; probable cases include persons with positive antigen results

Measure	Total	ChangeDirection	Change
COVID-19 Cases (confirmed and probable)	294,328	+	373
COVID-19 Tests Reported (molecular and antigen)	7,232,957	+	15,362
Daily Test Positivity*			2.43%
Patients Currently Hospitalized with COVID-19	402	-	1
COVID-19-Associated Deaths	7,807	+	8

Daily test positivity is the number of new positive molecular and antigen cases divided by the number of new molecular and antigen tests reported in the past 24 hours.


Healthcare Personnel
Medical First Responders
Long-Term Care Facility Residents & Staff
Residents & Staff of Congregate Settings
Educators & Child Care Providers
Individuals 55 and Older
Starting March 19
Starting April 5
Individuals 45-54 years old
Individuals 16 and Older

Percent of Population Who Have at Least One Dose of COVID-19 Vaccination

As reported to the CT Immunization Registry (CT WiZ)



Percent of Connecticut Population With a First Dose of COVID-19 Vaccine



Data are provisional and subject to change. Data as reported to CT WiZ (the CT Immunization Information System).

COVID-19 Vaccine Biweekly Update –Monday, Mar 16

Doses administered – *Preliminary Data*

	Doses administered in last 7 days			Total cumulative doses		
	First doses	Second doses	Total doses	First doses	Second doses	Total doses
Total	**137,049**	**69,679**	**206,728**	**918,741**	**460,756**	**1,379,497**
Pfizer & Moderna	114,297	69,679	183,976	883,491	460,756	1,344,247
Janssen (J&J)	22,752	N/A	22,752	35,250	N/A	35,250

**Data is preliminary and likely an undercount due to reporting lags. Data is subject to additional data cleaning and de-duplication.*

Total doses administered by age group

	At Least One Dose Administered		Percentage of Age Group Received at Least One Dose		Total Doses Administered**			Percentage of age group received	
	Pfizer & Moderna	Janssen (J&J)	P&M 1st Doses	J&J 1st Doses	At Least One Dose	Fully Vaccinated	Total doses	At Least One Dose	Fully Vaccinated
16-24	24,316	1,077	5.6%	0.3%	25,393	16,196	40,512	5.9%	3.7%
25-34	61,538	2,621	13.7%	0.6%	64,159	42,428	103,966	14.3%	9.5%
35-44	67,592	3,596	15.8%	0.8%	71,188	44,491	112,083	16.7%	10.4%
45-54	81,021	4,489	17.0%	0.9%	85,510	53,215	134,236	17.9%	11.2%
55-64	187,734	19,589	36.6%	3.8%	207,323	75,661	263,395	40.4%	14.7%
65-74	247,746	3,023	70.2%	0.9%	250,769	92,790	340,536	71.1%	26.3%
75-84	149,860	579	80.5%	0.3%	150,439	120,121	269,981	80.8%	64.6%
85+	63,184	253	69.2%	0.3%	63,437	50,897	114,081	69.5%	55.7%
Total	**882,991**	**35,227**			**918,218**	**495,799**	**1,378,790**		

** Data is preliminary and subject to additional verification. "At least one dose" includes J&J as well as first doses of Moderna and Pfizer. "Fully vaccinated" includes individuals who have received J&J or two doses of either Pfizer or Moderna.*

Doses shipped & delivered

	Shipments arriving this week			Cumulative arrived as of last week		
	(Mar 15 – Mar 21)			(Dec 14 – Mar 14)		
	First doses	Second doses	Total doses	First doses	Second doses	Total doses
State Allocation	**89,140**	**72,070**	**161,210**	**743,855**	**454,430**	**1,198,285**
Pfizer	49,140	36,270	85,410	325,455	213,330	538,785
Moderna	35,800	35,800	71,600	384,600	241,100	625,700
Janssen (J&J)	4,200	N/A	4,200	33,800	N/A	33,800
Federal Retail Pharmacy Program (FRPP)	**27,710**	**11,700**	**39,410**	**107,930**	**28,950**	**136,880**
Pfizer	15,210	11,700	26,910	57,330	17,550	74,880
Moderna	11,200	0	11,200	45,000	11,400	56,400
Janssen (J&J)	1,300	N/A	1,300	5,600	N/A	5,600
Federally Qualified Health Center Supplemental Program	**13,950**	**0**	**13,950**	**44,360**	**0**	**44,360**
Pfizer	7,500	0	7,500	9,360	0	9,360
Moderna	5,850	0	5,850	31,700	0	31,700
Janssen (J&J)	600	N/A	600	3,300	N/A	3,300
Long Term Care*	**0**	**0**	**0**	**74,100**	**74,100**	**148,200**
Total	**130,800**	**83,770**	**214,570**	**970,245**	**557,480**	**1,527,725**

** 23,595 doses were transferred to the state allocation from long term care. Additionally, CVS and Walgreens re-purposed a combined 35,100 doses from the long-term care program for use in their store locations.*

Key messages & updates

- As of Sunday night, **1,379,497 doses of vaccine had been administered, including 918,741 first doses.**
- **40% of individuals between 55-64 have received at least one dose of vaccine while over 70% of individuals between 65-74 have received at least one dose** of vaccine.
- With the 55-64 age cohort approaching 50% with a first dose of vaccine and increasing supplies of vaccine from the federal government, **Connecticut will open up vaccine scheduling to individuals 45 years of age and older starting on Friday, March 19th, several days ahead of schedule.**
- In addition, **the final two age groups, 35-44 and 16-34, will be combined into one group, with scheduling anticipated to start for the 16+ group on April 5th. This means vaccine will be available to all Connecticut residents over the age of 16 about a month earlier than previously estimated.**
- DPH will work with providers and the Department of Developmental Services to **prioritize vaccine access for the most medically high-risk individuals under 45 during the month of April**.
- **CT has three effective vaccines available.** DPH does not recommend shopping around for a vaccine brand, which could cause delays in getting vaccinated. ***The best shot for people to get is the one that is available to them.***
- **All three vaccines are highly effective in preventing serious illness, hospitalization, and death from COVID.** The vaccines also have comparable safety profiles.
- The **J&J vaccine has the added benefit in that it is a single shot**.
- **Side effects from the J&J vaccine are similar to those reported for the Pfizer and Moderna vaccines**: pain at injection site, fever, headache, muscle aches, nausea, fatigue.
- While not experienced by everyone, **side effects for all three vaccines are a normal sign that the body is building protections against the COVID-19 virus**
- **It remains important for everyone, even those who are fully vaccinated, to continue to wear masks, social distance, practice good hand hygiene, stay home when sick, and get tested** if you have symptoms of COVID-19.

Johnson & Johnson Vaccine Information Points

March 1, 2021

- **The FDA has issued an emergency use authorization for the Janssen Johnson & Johnson (J&J) COVID-19 vaccine.**
- **This means there are now three effective vaccines available.**
- **All three vaccines are highly effective in preventing serious illness, hospitalization, and death from COVID. The vaccines also have comparable safety profiles.**
- **The three vaccines are not the same and they should not be compared: J&J vaccine is not an mRNA vaccine (like Moderna and Pfizer) and its clinical trials were conducted in different locations and at a time when more COVID strains were circulating, so J&J's efficacy is going to look different than the other two.**
- **The bottom line is all three vaccines are SAFE and HIGHLY EFFECTIVE against severe illness, hospitalization and death from COVID-19.**
- **The J&J vaccine has the added benefit in that it is a single shot.**
- **The J&J vaccine is a viral vector vaccine. It cannot give anyone COVID-19 or other infections. It does not affect or interact with our DNA in any way.**
- **The J&J vaccine is 85% effective against severe COVID-19.**
- **Connecticut will begin receiving supplies of the J&J vaccine as soon as the first week of March.**

- **This will increase the overall supply of vaccine and enable Connecticut to vaccinate more residents more quickly.**

- **The CDC and other public health experts advise that everyone get a COVID vaccine regardless of the manufacturer.**

- **The increase in vaccine supply means Connecticut will be able to vaccinate more people, more quickly, with greater fairness.**

- **For questions on when and how you can receive a vaccine visit the Connecticut Department of Public Health website at www.ct.gov/covidvaccine.**

Scheduling a COVID-19 vaccine appointment in Connecticut

If you live or work in Connecticut AND are currently eligible to receive a COVID-19 vaccine, there are multiple options for how you can schedule.

See below for a list of scheduling options (or scroll to the bottom of the page to search by location)

VAMS	VAMS is the Vaccine Administration Management System, and can be used to schedule appointments at multiple clinics across the State, including: • Trinity Health of New England • Griffin Hospital • Nuvance Hospital • … and many local health departments, FQHCs, and more …	Click here to learn more
 **Call the Vaccine Appointment Assist Line**	The Vaccine Appointment Assist Line is open 8a-8p, 7 days per week. By calling this line, you can schedule at locations in: • East Hartford • Middletown • Stamford • New Haven • Danbury • … and more …	Call **877-918-2224**
Hartford HealthCare	Hartford Healthcare has multiple locations throughout the State, including large clinics in the Hartford-area. You can use MyChart to schedule	Click here to schedule
Yale NewHaven Health	Yale New Haven Hospital has multiple locations throughout the State, including large clinics in the New Haven area. You can use MyChart to schedule	Click here to schedule

STAMFORD HEALTH	Stamford Health is operating a clinic 7-days-per-week at the Stamford Hospital. You can use ZocDoc to schedule	Click here to schedule
Walgreens	Walgreens is currently offering COVID Vaccine at 12 different locations – and will soon be adding many more across the State	Click here to schedule

CVS	CVS is currently offering vaccine in 4 stores (Colchester, Putnam, Waterford, and Windsor Locks) and will be expanding to 12 more in the next week	Click here to schedule
Walmart	Walmart will be offering COVID-19 vaccines at 7 locations across the State of Connecticut: Torrington, West Haven, North Windham, New Haven, Waterbury, Hartford and Norwalk	Click here to schedule

LATEST NURSING HOME REPORT (BY FACILITY) CAN BE FOUND HERE:

https://portal.ct.gov/-/media/Coronavirus/Nursing-Homes-and-Assisted-Living-Facilities-Data/20210311-Nursing-Homes-with-COVID-19.pdf

Number of COVID-19 Cases, Associated Deaths, and Rates per 100,000 by Age Groups



Total COVID-19 cases and associated deaths include confirmed plus probable.

COVID-19 Cases, Rate per 100,000, Associated Deaths, and Number Hospitalized by County

Cases and deaths are cumulative over time



COVID-19 cases, rate per 100,000, and associated deaths are by county of residence. Hospitalization data are collected by CT Hospital Association and represent the number of patients currently hospitalized by location of the hospital and not the patient residence.

Number of Confirmed and Probable COVID-19 Cases by Date

Test results may be reported several days after the result. Data are incomplete for the most recent days. Data from previous dates are routinely updated.



Number of COVID-19 Associated Deaths by Date of Death



All data are preliminary and subject to change. Data from previous dates are routinely updated.

Number of Patients Hospitalized with COVID-19 by Date



Data from previous dates are routinely updated.

Average Daily Rate of COVID-19 Cases Among Persons Living in Community Settings per 100,000 Population By Town



Cumulative Number of COVID-19 Cases by Town

Click Town for Additional Information



Total Number of Cases

0 - 5 | 6 - 50 | 51 - 100 | 101 - 200 | 201 - 500 | 501 - 1,000 | 1,001 - 5,000 | >5,000